Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
---|
11/07/2002 | WO2002087585A1 Compositions comprising lopinavir and methods for enhancing the bioavailability of pharmaceutical agents |
11/07/2002 | WO2002087562A1 Use of protein and essential amino acids to treat amenorrhea and related disorders |
11/07/2002 | WO2002087554A2 Ef-tu binding agent as antibacterial agent |
11/07/2002 | WO2002087548A1 A pharmaceutical tablet having a high api content |
11/07/2002 | WO2002087540A1 Artificial blood made of hemoglobin encapsulated in liposomes |
11/07/2002 | WO2002087531A1 Stabilised enzyme compositions |
11/07/2002 | WO2002087511A2 Modulators of elastase inhibitor secretion |
11/07/2002 | WO2002087510A2 Subcellular targeting of therapeutic proteins |
11/07/2002 | WO2002087509A2 Colloidal metal compositions and methods |
11/07/2002 | WO2002087507A2 Breast cancer-associated genes and uses thereof |
11/07/2002 | WO2002087504A2 Methods for inhibiting tumor cell proliferation |
11/07/2002 | WO2002087503A2 Compositions and methods for treating colorectal polyps and cancer |
11/07/2002 | WO2002087496A2 Methods for inhibiting macrophage colony stimulating factor and c-fms-dependent cell signaling |
11/07/2002 | WO2002087419A2 Biological pacemaker |
11/07/2002 | WO2002087417A2 Alleviation of the memory deficits and memory components of psychiatric dysfunctions by altering atypical pkm activity |
11/07/2002 | WO2002087336A1 Foot and mouth disease virus vaccine |
11/07/2002 | WO2002087304A2 Il2 peptides; peptides and peptide dimers both derived from interleukin-2 |
11/07/2002 | WO2002074980A3 Muteins of hypoxia inducible factor alpha and methods of use thereof |
11/07/2002 | WO2002072115A3 Vectors, compositions and methods for treating a vascular disorder |
11/07/2002 | WO2002068614A3 Interferon regulatory factor-1/human estrogen receptor fusion protein and its use for treating carcinomas |
11/07/2002 | WO2002067857A3 Modified annexin proteins and methods for preventing thrombosis |
11/07/2002 | WO2002057420A3 50 human secreted proteins |
11/07/2002 | WO2002052016A3 Regulation of human protein l-isoaspartate o-methyltransferase-like enzyme |
11/07/2002 | WO2002051352A3 New uses of insulin and pancreatin |
11/07/2002 | WO2002050084A3 Streptogramin derivatives preparation thereof and compositions containing same |
11/07/2002 | WO2002038586A3 Haplotypes of the il6 gene |
11/07/2002 | WO2002032938A3 Regulation of human pgc-1-like protein |
11/07/2002 | WO2002030972A3 Regulation of nf-at interacting protein nip 45 like protein |
11/07/2002 | WO2002028897A3 Human g-protein coupled receptor and uses thereof |
11/07/2002 | WO2002026823A3 A novel human g-protein coupled receptor, hgprbmy7, expressed highly in spinal cord |
11/07/2002 | WO2002024927A3 Regulation of human adam-ts 1 precursor-like protein |
11/07/2002 | WO2002024886A3 Regulation of human serine protease |
11/07/2002 | WO2002020565A3 Collections of repeat proteins comprising repeat modules |
11/07/2002 | WO2002012899A3 Peptides presented by cells |
11/07/2002 | WO2002009667A3 Dispersions for formulating slightly or poorly soluble active ingredients |
11/07/2002 | WO2001098503A3 Regulation of human eosinophil serine protease 1-like enzyme |
11/07/2002 | WO2001093888A3 A method of treatment of amyotrophic lateral sclerosis with a protein extractable from mammalian organs |
11/07/2002 | WO2001086002A9 Compositions, kits, and methods for identification, assessment, prevention, and therapy of psoriasis |
11/07/2002 | WO2001085768A9 G-protein coupled receptors and uses therefor |
11/07/2002 | WO2001073056A3 Regulation of human oxoprolinase-like enzyme |
11/07/2002 | WO2001057186A9 Methods and compositions for diagnosis and treatment of cancer based on esf |
11/07/2002 | WO2001049830A9 Improved lysosomal enzymes and lysosomal enzyme activators |
11/07/2002 | WO2001040449A9 Cloning of a gene encoding an amino acid racemase from trypanosoma cruzi, and uses thereof |
11/07/2002 | WO2001037859A3 Pharmaceutical compositions containing compounds which increase or decrease tmtnf levels |
11/07/2002 | WO2001027079A9 Compositions and methods of use of ligands that bind components of the blood coagulation/clotting pathway for the treatment of cancer and angiogenic-based disease |
11/07/2002 | WO2001026676A9 Methods of treating or preventing cell, tissue, and organ damage using human myeloid progenitor inhibitory factor-1 (mpif-1) |
11/07/2002 | WO2001010454A9 Pharmaceutical composition comprising peg-asparaginase for the treatment of hiv infection |
11/07/2002 | US20020166145 Coffee mannanase |
11/07/2002 | US20020166138 FLP-mediated gene modification in mammalian cells, and compositions and cells useful therefor |
11/07/2002 | US20020166136 Anti-inflammatory therapies using cytokine signaling regulated by a SOCS-3 promoter |
11/07/2002 | US20020166135 Modulation of preferential aspects of nervous system; obtain human, administer modulator, monitor expression of preferential neuropeptides in brain |
11/07/2002 | US20020166134 Cardiomyocytes with enhanced proliferative potenial, and methods for preparing and using same |
11/07/2002 | US20020166133 Neokine protein and nucleic acid molecules and uses therefor |
11/07/2002 | US20020166132 System for regulating in vivo the expression of a transgene by conditional inhibition |
11/07/2002 | US20020166131 Nucleotide sequences coding polypeptide for use in the treatment of disease parkinson's, irritable bowel syndrome and cardiovascular disorders |
11/07/2002 | US20020166130 Expression of active human factor IX in mammary tissue of transgenic animals |
11/07/2002 | US20020165617 Phospholipid-coated implants |
11/07/2002 | US20020165386 C-junction-n-terminal kinase (JNK); microbiocides; treating neurodegenerative diseases |
11/07/2002 | US20020165379 An isolated nucleic acid encoding a monomer of a calcium-activated potassium channel, and the monomer having molecular weight 40-80 kDa, unit conductance 2-6-pS, binding to antibodies generated against specific peptide sequence |
11/07/2002 | US20020165378 Human membrane antigen tm4 superfamily protein and dna encoding this protein |
11/07/2002 | US20020165377 ADAM polynucleotides, polypeptides, and antibodies |
11/07/2002 | US20020165374 Secreted protein HFEAF41 |
11/07/2002 | US20020165373 Contacting the sample with an isolated recombinant immunodominant Neospora antigen, forming an antigen/antibody complex, and detecting the presence or absence of the complex |
11/07/2002 | US20020165371 Compositions and methods for the therapy and diagnosis of breast cancer |
11/07/2002 | US20020165365 Synthetic catalyst for selective cleavage of protein and method for selective cleavage of protein using the same |
11/07/2002 | US20020165363 Cachexia remedy |
11/07/2002 | US20020165361 Antibody for use in the diagnosis and treatment of cell proliferation disorders |
11/07/2002 | US20020165358 Tumor cytotoxic factor for use in the treatment of cell proliferative and liver disorders |
11/07/2002 | US20020165357 38554, 57301 and 58324, human organic ion transporters and uses therefor |
11/07/2002 | US20020165355 Methylated, SmD homologous peptides, reactive with the antibodies from sera of living beings affected with systemic lupus erythematosus |
11/07/2002 | US20020165354 Nucleotide sequences coding polypeptides for use in the treatment of septic shock, cachexia, graft-versus host, autoimmune and rheumatic diseases |
11/07/2002 | US20020165353 Transport protein for use in human therapeutics and diagnostics |
11/07/2002 | US20020165350 Novel polypeptide, a method of producing it, and utility of the polypeptide |
11/07/2002 | US20020165347 Polypeptide for use in the diagnosis, prevention and treatment of arteriosclerosis and vascular restenosis |
11/07/2002 | US20020165345 Prostate cancer gene |
11/07/2002 | US20020165343 Growth hormone secretagogues |
11/07/2002 | US20020165342 Glucagon-like insulinotropic peptides, compositions and methods |
11/07/2002 | US20020165271 Topical composition where vitamin C made by contacting an ascorbic acid precursor with the exception of its esters with an enzyme; L-galactono-1,4-lactone converted with L-galactono-1,4-lactone dehydrogenase; stability |
11/07/2002 | US20020165265 Microtubule disrupter such as paclitaxel, and a polymeric carrier that is NOT a capsule; embolizing blood vessels, and eliminating biliary, urethral, esophageal, and tracheal/bronchial obstructions |
11/07/2002 | US20020165262 Methods and products relating to 16-HETE analogs |
11/07/2002 | US20020165237 Treatment of the insulin resistance syndrome |
11/07/2002 | US20020165233 Quinoxaline containing medicaments for post exposure prophylaxis of an HIV infection |
11/07/2002 | US20020165230 Gamma-ketoacid dipeptides as inhibitors of caspase-3 |
11/07/2002 | US20020165208 Administering testosterone inhibitor; polypeptide |
11/07/2002 | US20020165196 Oligonucleotide inhibitors of cancer cell proliferation |
11/07/2002 | US20020165195 Method of treating androgen-dependent disorders |
11/07/2002 | US20020165193 Compositions and methods of treating tumors |
11/07/2002 | US20020165192 Grafting bone marrow; using inositol polyphosphatase; antigen for blocking gene expression |
11/07/2002 | US20020165191 Spatial and temporal control of gene expression using a heat shock protein promoter in combination with local heat |
11/07/2002 | US20020165190 Expression vector coding p972 gene for cancer therapy and adenovirus producing the same |
11/07/2002 | US20020165189 Oligoribonucleotides and ribonucleases for cleaving RNA |
11/07/2002 | US20020165188 Methods for inhibition of tumorigenic properties of melanoma cells |
11/07/2002 | US20020165187 Isolated nucleic acids; therapy, diagnosis |
11/07/2002 | US20020165186 Compounds that affect CD83 expression, pharmaceutical compositions comprising said compounds and methods for identifying said compounds |
11/07/2002 | US20020165185 Novel Heparin-induced CCN-like molecules and uses therefor |
11/07/2002 | US20020165179 Multifunctional nanodevice platform |
11/07/2002 | US20020165178 Immunostimulatory nucleic acids for the treatment of anemia, thrombocytopenia, and neutropenia |
11/07/2002 | US20020165174 Methods and compositions for antisense VEGF oligonucleotides |
11/07/2002 | US20020165171 Delivery construct for antisense nucleic acids and methods of use |
11/07/2002 | US20020165166 Treating thrombosis by administering a CD154 inhibitor, such as a metalloproteinase inhibitor |